Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice

KC Gorson, IN van Schaik, ISJ (Ingemar) Merkies, RA Lewis, RJ Barohn, CL Koski, DR Cornblath, RAC Hughes, AF Hahn, M Baumgarten, J Goldstein, J Katz, M Graves, G Parry, Pieter van Doorn

Research output: Contribution to journalArticleAcademic

103 Citations (Scopus)


Defining long-term outcomes in chronic inflammatory demyelinating polyneuropathy (CIDP) has been complicated by varying definitions of treatment response and differing scales measuring impairment or disability. An expert panel was convened to devise a CIDP Disease Activity Status (CDAS) and to classify long-term outcome by applying it to 106 patients with a consensus diagnosis of CIDP. Sixty of these cases were graded blindly by three independent reviewers to assess inter-rater reliability. The mean duration of follow-up was 6.4 years (range, 3 months-23 years). Eleven percent of patients were classified as cured (stable examination and off treatment for >= 5 years), 20% were in remission (stable and off treatment for < 5 years), 44% had stable active disease but required ongoing therapy for at least 1 year, 7% were improving after recent initiation of therapy, and 18% had unstable active disease (treatment naive or treatment refractory). Excellent inter-rater reliability was observed (kappa scores: 0.93-0.97; p < 0.0001). The CDAS is considered a simple and reproducible tool to classify patients with CIDP according to disease activity and treatment status that can be applied easily in practice and potentially to select patients for clinical trials.
Original languageUndefined/Unknown
Pages (from-to)326-333
Number of pages8
JournalJournal of the Peripheral Nervous System
Issue number4
Publication statusPublished - 2010

Cite this